CJC-1295 – With DAC 10mg

Description

Strength: 10mg
CAS: 863288-34-0
Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular weight: 3648.4 g/mol
Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Malimide-beta-Ala)-NH2
Synonyms: CJC1295, CJC-1295 with DAC
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

CJC-1295 – With DAC (10 mg) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH). It contains multiple amino acids modified to enhance stability and includes a Drug Affinity Complex (DAC) designed to extend its half-life in research models.

CJC-1295 with DAC has been studied for its prolonged interaction with growth hormone regulatory pathways in preclinical and early-phase human pharmacokinetic studies. The DAC component allows reversible binding to circulating albumin, extending peptide activity in experimental models.

This product is supplied as a 10 mg lyophilized powder in a sterile vial. Shelf life is 24 months under recommended storage conditions.

• Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Malimide-beta-Ala)-NH2
• Molecular formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular weight: 3648.4 g/mol
• CAS number: 863288-34-0
• Supplied as 10 mg lyophilized powder in sterile vial
• Contains Drug Affinity Complex (DAC) for extended activity in research models
• Storage: 2–8 °C (≤–20 °C for long-term storage)
• For laboratory research use only

CJC-1295 with DAC is being researched for its role in stimulating endogenous growth hormone release through interaction with GHRH-related pathways. In laboratory settings, it has been studied for its prolonged signaling profile due to its extended circulation time. In early-phase human studies, the estimated terminal half-life was reported at approximately 5.8–8.1 days.

Research applications have included:

• Endocrine system studies
• Growth hormone secretion research
• Metabolic regulation investigations
• Body composition research models

The DAC modification allows the peptide to bind to circulating albumin in experimental systems, which prolongs exposure compared to shorter-acting GHRH analogs.

Research remains investigational and limited to controlled study environments.

Published studies have evaluated CJC-1295 with DAC in controlled research settings, including early-phase human research studies and animal models.

Reported research dosing has included:

• Microgram-based dosing in early-phase human research studies
• Weekly or less frequent administration schedules in certain protocols
• Subcutaneous administration in controlled experimental settings

Observed effects in research have included sustained elevations in circulating growth hormone and related biomarkers over extended periods compared to shorter-acting analogs. These findings are limited to research contexts and do not constitute clinical recommendations. No approved therapeutic dosing guidelines exist.

• Store at 2–8 °C for routine handling
• For long-term storage, maintain at ≤–20 °C
• Avoid repeated freeze–thaw cycles
• Reconstitute using sterile laboratory-grade solvent under aseptic conditions
• Handle using appropriate laboratory protective equipment
• Dispose of materials in accordance with institutional biosafety and chemical handling guidelines

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
3. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. doi:10.1016/j.ghir.2009.03.001

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.